MedPath

Cartesian Therapeutics, Inc. (United States)

Cartesian Therapeutics, Inc. (United States) logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2016-01-01
Employees
11
Market Cap
$300.2M
Website
http://www.cartesiantherapeutics.com

Clinical Trials

11

Active:2
Completed:1

Trial Phases

4 Phases

Phase 1:5
Phase 2:4
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (45.5%)
Phase 2
4 (36.4%)
Not Applicable
1 (9.1%)
Phase 3
1 (9.1%)

Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis

Not Applicable
Not yet recruiting
Conditions
Childhood-onset Systemic Lupus Erythematous
ANCA-Associated Vasculitis (AAV)
Juvenile Myasthenia Gravis
Juvenile Dermatomyositis
Interventions
First Posted Date
2025-07-28
Last Posted Date
2025-07-28
Lead Sponsor
Cartesian Therapeutics
Target Recruit Count
50
Registration Number
NCT07089121

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

Phase 3
Recruiting
Conditions
Myasthaenia Gravis
Interventions
Biological: Decartes-08
Other: Placebo Drug
First Posted Date
2025-01-29
Last Posted Date
2025-09-04
Lead Sponsor
Cartesian Therapeutics
Target Recruit Count
100
Registration Number
NCT06799247
Locations
🇺🇸

A14, Orange, California, United States

🇺🇸

A22, Chapel Hill, North Carolina, United States

🇷🇸

A24, Belgrade, Serbia

and more 5 locations

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Interventions
First Posted Date
2024-03-12
Last Posted Date
2025-05-29
Lead Sponsor
Cartesian Therapeutics
Target Recruit Count
4
Registration Number
NCT06304636
Locations
🇺🇸

Center for Cancer and Blood Disorders (AON), Bethesda, Maryland, United States

Descartes-08 for Patients With Systemic Lupus Erythematosus

Phase 2
Recruiting
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
First Posted Date
2023-09-14
Last Posted Date
2025-04-16
Lead Sponsor
Cartesian Therapeutics
Target Recruit Count
30
Registration Number
NCT06038474
Locations
🇺🇸

Profound Research LLC, Oceanside, California, United States

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Relapse Multiple Myeloma
Multiple Myeloma
Interventions
First Posted Date
2021-11-09
Last Posted Date
2024-11-12
Lead Sponsor
Cartesian Therapeutics
Target Recruit Count
9
Registration Number
NCT05113342
Locations
🇺🇸

Louisiana State University Health Science Center at Shreveport, Shreveport, Louisiana, United States

🇺🇸

Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

🇹🇷

Saglik Bilimleri Universitesi, Ankara, Anatolia, Turkey

  • Prev
  • 1
  • 2
  • 3
  • Next

News

Biotech Stocks Surge After-Hours as Investors Anticipate Key Clinical Trial Results

MBX Biosciences shares jumped 33% after-hours ahead of Phase 2 topline results for Canvuparatide, a once-weekly therapy for chronic hypoparathyroidism, scheduled for release on Monday.

FDA Approves Nipocalimab for Myasthenia Gravis as Pipeline Advances with 20+ Novel Therapies

The FDA approved nipocalimab (Imaavy) in May 2025 as the first therapy targeting the underlying cause of generalized myasthenia gravis in patients aged 12 and older with specific antibodies.

Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies

The myasthenia gravis market across seven major markets is projected to grow from $6.1 billion in 2024 to $10.3 billion by 2034, representing a 5.3% compound annual growth rate.

CAR T-cell Therapy Pipeline Surges with 180+ Companies Advancing Novel Cancer Treatments

The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.

Cartesian Therapeutics' Descartes-08 Shows Promise in Myasthenia Gravis Phase 3 Trial

Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission.

Novel Therapies and Vaccines Poised to Reshape Community Pharmacy in 2025

Insulin icodec, a once-weekly basal insulin analog, demonstrated positive safety and efficacy in phase 3 trials for type 2 diabetes, potentially reducing injection burden and improving adherence.

Cartesian Therapeutics Advances mRNA Cell Therapies for Autoimmune Diseases

Cartesian Therapeutics is set to begin Phase 3 AURORA trial of Descartes-08 for myasthenia gravis in the first half of 2025.

CAR T-Cell Therapy Shows Promise in Treating Autoimmune Diseases: Clinical Trials and Future Directions

UChicago Medicine launched a Phase 2 clinical trial to explore CAR T-cell therapy for systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis.

Cartesian Therapeutics Advances Myasthenia Gravis Treatment with Phase 3 Trial of Descartes-08

Cartesian Therapeutics is set to begin a Phase 3 trial (AURORA) for Descartes-08, an mRNA CAR-T therapy, in patients with acetylcholine receptor autoantibody positive (AChR Ab+) myasthenia gravis (MG).

Cartesian Therapeutics' Descartes-08 Receives FDA Agreement for Phase 3 Myasthenia Gravis Trial

Cartesian Therapeutics received FDA agreement under the Special Protocol Assessment for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.